Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi XDC to Offer GeneQuantum’s Platforms for Bioconjugate Development

publication date: Dec 27, 2022

WuXi XDC, a bioconjugate CRMO, will promote Suzhou GeneQuantum Healthcare’s drug development platforms globally to advance innovative bioconjugate development and commercial production. GeneQuantum has developed a proprietary enzymatic site-specific conjugation technology to develop ADC drugs more quickly than other methods. WuXi XDC is a joint venture between WuXi Biologics and WuXi STA that provides contract CRMO services for bioconjugates, including antibody drug conjugates. GeneQuantum will also collaborate with Wuxi XDC to develop several of its own ADC candidates using Wuxi XDC's ADC production platform and CMC capability. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital